Hyland Megan H, Cohen Jeffrey A
Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
Neurol Clin Pract. 2011 Dec;1(1):61-65. doi: 10.1212/CPJ.0b013e31823c51dd.
Fingolimod is the first oral disease therapy approved for relapsing-remitting multiple sclerosis (MS). Patients can be switched directly from interferon-β or glatiramer acetate to fingolimod without a washout period. Fingolimod's potent efficacy, oral route of administration, and generally good safety and tolerability make it appealing to patients and clinicians. However, several adverse effects have already been identified, overall experience with its use is limited compared to other agents, and its novel and complex mechanism of action make predicting adverse effects challenging. Fingolimod's place in the MS treatment algorithm is evolving. We anticipate that once centers have solved the logistical issues associated with fingolimod initiation and if the experience in clinical practice parallels the efficacy, safety, and tolerability demonstrated in the phase 3 trials, fingolimod's routine use will increase.
芬戈莫德是首个被批准用于复发缓解型多发性硬化症（MS）的口服疾病治疗药物。患者可以直接从干扰素-β或醋酸格拉替雷转换为芬戈莫德，无需洗脱期。芬戈莫德强大的疗效、口服给药途径以及总体良好的安全性和耐受性使其对患者和临床医生具有吸引力。然而，已经发现了几种不良反应，与其他药物相比，其使用的总体经验有限，并且其新颖而复杂的作用机制使得预测不良反应具有挑战性。芬戈莫德在MS治疗方案中的地位正在不断演变。我们预计，一旦各中心解决了与启动芬戈莫德相关的后勤问题，并且如果临床实践中的经验与3期试验中证明的疗效、安全性和耐受性相似，芬戈莫德的常规使用将会增加。
